Can Medicare Cover Medical Marijuana? What Recent Federal Action Means for Patients
The conversation around medical marijuana and cannabidiol (CBD) has shifted significantly in the United States — especially for older adults and Medicare beneficiaries. Between longstanding federal limitations and recent policy changes aimed at expanding medical research, it’s important to understand where coverage stands today and how things may evolve.
Medicare Today: No Standard Coverage for Medical Marijuana
Currently, Medicare does not cover medical marijuana. According to an updated FAQ from AARP, the primary reason is that marijuana remains classified as a Schedule I controlled substance under federal law — meaning it is considered to have no currently accepted medical use and a high potential for abuse. Because of this classification, Medicare cannot cover marijuana products a patient might purchase from a dispensary, even when a physician recommends them. AARP
However, Medicare may cover certain FDA-approved drugs derived from cannabis — for example, prescription products that contain specific cannabinoids and have been approved for therapeutic use. AARP
That distinction is important: patients often hear “medical marijuana” used broadly, but Medicare’s coverage rules hinge on whether a product has FDA approval and whether it fits within established prescription drug coverage rules.
For the detailed AARP overview of Medicare’s stance on medical marijuana and CBD, see “Does Medicare Cover Medical Marijuana or CBD?”:
https://www.aarp.org/medicare/faq/does-medicare-cover-medical-marijuana/
A Potential Shift: Federal Policy to Expand Research
In December 2025, the White House issued an executive action titled “Increasing Medical Marijuana and Cannabidiol Research.” This policy — set forth in a presidential action — signals a federal priority to expand research on medical marijuana and CBD. Its goal is to improve scientific understanding of both the risks and benefits of these products for patients and clinicians. The White House
The administration has stated that closing the gap between widespread medical use and scientific knowledge is critical, and that enhanced research could help inform future therapeutic decisions. The White House
For those interested in the official policy statement and context, see “Increasing Medical Marijuana and Cannabidiol Research” on the White House website:
https://www.whitehouse.gov/presidential-actions/2025/12/increasing-medical-marijuana-and-cannabidiol-research/
Why This Matters for Medicare Beneficiaries
Although the executive policy does not immediately change Medicare coverage rules, the emphasis on research could have downstream effects, such as:
-
Increasing scientific evidence supporting the safety and efficacy of marijuana and CBD in treating various conditions.
-
Encouraging FDA-approved cannabis-derived therapeutic products, which could eventually be covered if approved and prescribed.
-
Informing long-term policy changes that may reshape federal scheduling or coverage guidelines.
Already, Medicare officials have discussed potential pilot programs that would test coverage for certain hemp-derived CBD products for beneficiaries with specific health conditions, pending further regulatory work. AARP
Looking Ahead
Medicare’s current position remains grounded in federal drug classification and regulatory barriers, but federal initiatives to expand medical marijuana and cannabidiol research represent a meaningful shift toward evidence-based policy. As that research advances, it may create the data and regulatory foundation needed for future coverage considerations.
For anyone navigating medical marijuana or CBD for health reasons, it is advisable to:
-
Consult directly with healthcare providers about appropriate products and evidence.
-
Monitor federal policy developments and FDA approvals that could influence insurance coverage.
-
Understand your state’s medical marijuana laws, which may be more permissive than federal standards.
As this landscape evolves, Medicare beneficiaries and their caregivers will benefit from staying informed and engaged with both healthcare professionals and policy changes in Washington.
